Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

AMN Healthcare Names Jeffrey R. Knudson as Chief Financial Officer
AMN Healthcare Names Jeffrey R. Knudson as Chief Financial Officer


AMN Healthcare (NYSE:AMN), the nation’s largest total talent solutions provider in healthcare, announced the appointment of Jeffrey R. Knudson as the company’s Chief Financial Officer. He will join

Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Lucid Diagnostics Announces Pricing of Initial Public Offering
Lucid Diagnostics Announces Pricing of Initial Public Offering


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced

Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call


Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2021 financial results on Wednesday, November 3rd, before the market opens. A conference call has been

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer:
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer


Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of

Simulations Plus Announces Cash Dividend: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Cash Dividend


Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 1

Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK


DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awareness and education

Charles River Laboratories Announces Two Divestitures: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Two Divestitures


Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has divested its Research Models and Services operations in Japan (RMS Japan) and its gene therapy CDMO site in Sweden

Humana Continues Extensive Statewide Expansion in Tennessee: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Continues Extensive Statewide Expansion in Tennessee


Leading health and well-being company Humana Inc. (NYSE: HUM) today announced another major expansion of its Medicare Advantage (MA) offerings across Tennessee for the 2022 plan year. It’s part of

Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

Vifor Pharma announces changes to its Executive Committee: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma announces changes to its Executive Committee


Regulatory News:



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and

Hanger Announces Date of 2021 Third Quarter Earnings Release and Conference Call
Hanger Announces Date of 2021 Third Quarter Earnings Release and Conference Call


Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced it will report its financial results for the third quarter and nine months

Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call


Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2021, ended August 31, 2021, after the close of the

Acadia Healthcare Names Osei Mevs as Vice President of Government Relations: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Names Osei Mevs as Vice President of Government Relations


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that J.L. Osei Mevs has been named Vice President of Government Relations. In this role, Mevs will oversee the Company’s government

Acadia Healthcare Names David Keys as Chief Development Officer: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Names David Keys as Chief Development Officer


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that David M. Keys, CFA, has been named Chief Development Officer. Keys will focus on mergers & acquisitions, de novo development and

ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal


Regulatory News:



ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies

Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Third Quarter 2021 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its third quarter 2021 results on Thursday, October 28, 2021, after the close of the market. Acadia will conduct

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital


Regulatory News:



Nanobiotix (Paris:NANO) (NASDAQ:NBTX):



Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com


Date


Number of Shares



Outstanding

Savara to Present at the Inaugural Piper Sandler Lung Day: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at the Inaugural Piper Sandler Lung Day


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the

Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021
Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results

 
Quantum Genomics and its partners reach a new stage of development in Asia
Quantum Genomics and its partners reach a new stage of development in Asia

Quantum Genomics and its partners reach a new stage of development in Asia

  • The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and
Humana Expands Access to Affordable Medicare Options in Eastern North Carolina: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Access to Affordable Medicare Options in Eastern North Carolina


Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it is introducing a new affordable, whole person health care Medicare Advantage PPO plan in rural communities located

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced the